BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

...have low efficacy or tolerability issues, or both. PDE-4 inhibitors on the market are Eucrisa crisaborole...
...atopic dermatitis, and oral Otezla apremilast from Celgene Corp. to treat psoriasis. According to Watanabe, Eucrisa...
...by blocking PDE-4.” ARQ-151 is a PDE-4 inhibitor at least 50 times as potent as Eucrisa...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Apr 15, 2017
Strategy

WAC-a-mol

...International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec References Institute for Clinical and Economic Review. “Dupilumab and crisaborole...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...with disease progression on or after a platinum-based therapy Pfizer Inc. (NYSE:PFE) FDA approves Eucrisa crisaborole...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Dec 16, 2016
Regulation

Blip or dip?

...since 2006. FDA has approved at least one other therapy since the cutoff date: Eucrisa crisaborole...
BioCentury | Dec 15, 2016
Clinical News

Eucrisa regulatory update

...FDA approved an NDA from Pfizer for Eucrisa crisaborole 2% ointment to treat mild to moderate...
...to moderate atopic dermatitis in patients ages ≥2. Pfizer said the company plans to launch Eucrisa...
...Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Eucrisa crisaborole (formerly AN2728) Business: Dermatology Julian Zhu crisaborole Pfizer Inc. Phosphodiesterase-4 (PDE-4) Eucrisa...
BioCentury | Dec 15, 2016
Company News

FDA approves Pfizer eczema drug Eucrisa

...FDA approved Eucrisa crisaborole (formerly AN2728 ) from Pfizer Inc. (NYSE:PFE) to treat mild to moderate...
...patients aged two and older. Pfizer spokesperson Steven Danehy said the company plans to launch Eucrisa...
...end of January at a wholesale acquisition cost (WAC) of $580 per 60 g tube. Eucrisa...
BioCentury | May 23, 2016
Company News

Anacor, Pfizer deal

...Anacor’s close of $64.03 on May 13, before the deal was announced. Anacor’s crisaborole ( AN2728...
...to moderate atopic dermatitis in children and adults; the PDUFA date is Jan. 7, 2017. Crisaborole...
BioCentury | May 17, 2016
Top Story

Pfizer acquiring Anacor for $5.2B

...Inc. (NYSE:PFE) will acquire Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), giving it atopic dermatitis candidate crisaborole ( AN2728...
...premium to Anacor's close of $64.03 on Friday, before the deal was announced. Pfizer said crisaborole...
...to moderate atopic dermatitis in children and adults. Its PDUFA date is Jan. 7, 2017. Crisaborole...
Items per page:
1 - 10 of 54